Literature DB >> 21933333

Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer.

Einar Servoll1, Thorstein Saeter, Ljiljana Vlatkovic, Tormod Lund, Jahn Nesland, Gudmund Waaler, Karol Axcrona, Hans O Beisland.   

Abstract

UNLABELLED: Study Type - Prognosis (case series) Level of Evidence 4 What's known on the subject? and What does the study add? It is known that a tertiary Gleason grade pattern 4 or 5 found in RP specimens has a negative impact on recurrence rate regarding biochemical relapse after radical prostatectomy. This is the first publication addressing clinical outcome in patients with a tertiary Gleason grade pattern 4 or 5 showing a negative influence on clinical failure rates.
OBJECTIVE: To investigate the impact of a tertiary Gleason grade (TGG) pattern 4 or 5 on clinical failure, as the presence of a TGG pattern 4 or 5 in radical prostatectomy (RP) specimens has been associated with biochemical failure. PATIENTS AND METHODS: In all, 151 consecutive patients undergoing RP between 1985 and 2006 were reviewed, and 148 patients met study inclusion criteria. The RP specimens were pathologically re-examined and the presence of a TGG pattern 4 or 5 was recorded. The endpoint was clinical failure defined as local recurrence and/or development of metastasis at a mean follow-up of 108 months. Univariate analyses were performed using the Kaplan-Meier method. Multivariate analyses were performed using Cox proportional hazards regression.
RESULTS: Clinical failure was more likely among men with presence of a TGG pattern 4 or 5 than in men without a TGG pattern 4 or 5 (P= 0.006). In the subgroup of patients with Gleason score 7 the presence of a TGG 5 was significantly associated with clinical failure rate (P= 0.002). In patients with Gleason score <7 or >7, a TGG pattern 4 or 5 was not associated with increased failure rates. Multivariate Cox regression analyses in patients with Gleason score 7 showed that a TGG pattern 5 was a statistically significant predictor of clinical failure when adjusting for pathological stage, surgical margin status, extraprostatic extension and seminal vesicle invasion (hazard ratio 4.03, 95% confidence interval 1.72-9.46; P= 0.001). Further subgroup analyses showed that a TGG pattern 5 was associated with statistically higher clinical progression rates in patients with Gleason score 3 + 4 (P= 0.03). In patients with Gleason score 4 + 3, a TGG pattern 5 was associated with a trend towards a higher clinical progression rate, although this was not statistically significant (P= 0.189).
CONCLUSION: A TGG pattern 4 or 5 is associated with decreased clinical recurrence-free survival in Gleason score 7.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2011        PMID: 21933333     DOI: 10.1111/j.1464-410X.2011.10583.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  11 in total

1.  Concordance of Gleason grading with three-dimensional ultrasound systematic biopsy and biopsy core pre-embedding.

Authors:  Anouk A M A van der Aa; Christophe K Mannaerts; Hans van der Linden; Maudy Gayet; Bart Ph Schrier; Massimo Mischi; Harrie P Beerlage; Hessel Wijkstra
Journal:  World J Urol       Date:  2018-02-01       Impact factor: 4.226

2.  The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy.

Authors:  Christian Arsov; Nikolaus Becker; Robert Rabenalt; Andreas Hiester; Michael Quentin; Frederic Dietzel; Gerald Antoch; Helmut E Gabbert; Peter Albers; Lars Schimmöller
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-27       Impact factor: 4.553

Review 3.  Defining the threshold for significant versus insignificant prostate cancer.

Authors:  Theo H Van der Kwast; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

4.  Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.

Authors:  Chirag Doshi; Michael Vacchio; Kristopher Attwood; Christine Murekeyisoni; Diana C Mehedint; Shervin Badkhshan; Gissou Azabdaftari; Norbert Sule; Khurshid A Guru; James L Mohler; Eric C Kauffman
Journal:  Prostate       Date:  2016-02-16       Impact factor: 4.104

5.  Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men.

Authors:  Hong Zhang; Edward M Messing; Lois B Travis; Ollivier Hyrien; Rui Chen; Michael T Milano; Yuhchyau Chen
Journal:  Front Oncol       Date:  2013-12-23       Impact factor: 6.244

6.  Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time.

Authors:  Sigve Andersen; Elin Richardsen; Yngve Nordby; Nora Ness; Oystein Størkersen; Khalid Al-Shibli; Tom Donnem; Helena Bertilsson; Lill-Tove Busund; Anders Angelsen; Roy M Bremnes
Journal:  BMC Urol       Date:  2014-06-14       Impact factor: 2.264

7.  Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series.

Authors:  Zachary B Koloff; Daniel A Hamstra; John T Wei; Jeffrey S Montgomery; Scott A Tomlins; Angela J Wu; Todd M Morgan; Javed Siddiqui; Kellie Paich; Arul M Chinnaiyan; Felix Y Feng; Alon Z Weizer; Lakshmi P Kunju; Brent K Hollenbeck; David C Miller; Ganesh S Palapattu; Rohit Mehra
Journal:  Asian J Urol       Date:  2015-04-16

8.  Oncologic outcomes of patients with Gleason score 7 and tertiary Gleason pattern 5 after radical prostatectomy.

Authors:  Yi-Hsueh Leng; Won Jun Lee; Seung Ok Yang; Jeong Ki Lee; Tae Young Jung; Yun Beom Kim
Journal:  Korean J Urol       Date:  2013-09-10

9.  The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.

Authors:  Geert J L H van Leenders; Theodorus H van der Kwast; David J Grignon; Andrew J Evans; Glen Kristiansen; Charlotte F Kweldam; Geert Litjens; Jesse K McKenney; Jonathan Melamed; Nicholas Mottet; Gladell P Paner; Hemamali Samaratunga; Ivo G Schoots; Jeffry P Simko; Toyonori Tsuzuki; Murali Varma; Anne Y Warren; Thomas M Wheeler; Sean R Williamson; Kenneth A Iczkowski
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.298

10.  Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.

Authors:  Eva Hollemans; Esther I Verhoef; Chris H Bangma; John Rietbergen; Monique J Roobol; Jozien Helleman; Geert J L H van Leenders
Journal:  Histopathology       Date:  2020-04       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.